Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis

Figure 1 Study flow diagram.

Figure 2 A forest plots for the incidence of gastric cancer between Helicobacter pylori-eradication group and non-eradication group in 16 studies combined with randomized control studies and cohort studies (A), 4 randomized control studies (B) and 12 cohort studies (C) in non-gastric cancer patients with atrophic gastritis. There was no heterogeneity in the total analysis (I² = 30%, P = 0.13), randomized control studies (I² = 17%, P = 0.31) and cohort studies (I² = 18%, P = 0.26). A: Randomized control studies + Cohort studies; B: Randomized control studies; C: Cohort studies.

Figure 3 A forest plots for the incidence of metachronous gastric cancer between Helicobacter pylori-eradication group and non-eradication group in 22 studies combined with randomized control studies and cohort studies (A), 4 randomized control studies (B) and 18 cohort studies (C) in patients after endoscopic and operative resection. No heterogeneity in the total analysis (I² = 21%, P = 0.19), Randomized control studies (I² = 0%, P = 0.40) and cohort studies (I² = 28%, P = 0.13) was shown. A: Randomized control studies + Cohort studies; B: Randomized control studies; C: Cohort studies.

Figure 4 Forest plots of the incidence of gastric cancer between Helicobacter pylori-negative and positive groups with atrophic gastritis in studies published in different countries; 10 studies from Japan (A) and 5 from China (B). Forest plots of the incidence of metachronous gastric cancer between Helicobacter pylori-negative and positive groups presenting with gastric cancer in 7 studies from Japan (C) and 15 from South Korea (D). A: Non-gastric cancer patients with atrophic gastritis: Japan; B: Non-gastric cancer patients with atrophic gastritis: China; C: Metachronous gastric cancer: Japan; D: Metachronous gastric cancer: South Korea.

Figure 5 Forest plots of the incidence of gastric cancer between Helicobacter pylori-negative and -positive groups with atrophic gastritis in studies of different observation period length, < 5 years (A) and > 5 years (B). Forest plots of the incidence of metachronous gastric cancer in cases treated for gastric cancer in studies of different observation period length, < 5 years (C) and > 5 years (D). A: Non-gastric cancer with atrophic gastritis: within 5 years of resection; B: Non-gastric cancer with atrophic gastritis: more than 5 years after resection; C: Metachronous cancer: within 5 years of resection; D: Metachronous cancer: more than 5 years after resection.